We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) closed at $146.18 in the latest trading session, marking a +1.75% move from the prior day. The stock outpaced the S&P 500's daily loss of 1.11%. Elsewhere, the Dow saw a downswing of 0.42%, while the tech-heavy Nasdaq depreciated by 1.89%.
Heading into today, shares of the world's biggest maker of health care products had lost 3.97% over the past month, outpacing the Medical sector's loss of 6.22% and lagging the S&P 500's loss of 1.7% in that time.
Investors will be eagerly watching for the performance of Johnson & Johnson in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on January 22, 2025. The company is predicted to post an EPS of $2, indicating a 12.66% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $22.54 billion, indicating a 5.37% upward movement from the same quarter last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Johnson & Johnson. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.03% higher. Currently, Johnson & Johnson is carrying a Zacks Rank of #2 (Buy).
From a valuation perspective, Johnson & Johnson is currently exchanging hands at a Forward P/E ratio of 13.62. This denotes a premium relative to the industry's average Forward P/E of 12.34.
One should further note that JNJ currently holds a PEG ratio of 2.33. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.26.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 191, this industry ranks in the bottom 24% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors
Johnson & Johnson (JNJ - Free Report) closed at $146.18 in the latest trading session, marking a +1.75% move from the prior day. The stock outpaced the S&P 500's daily loss of 1.11%. Elsewhere, the Dow saw a downswing of 0.42%, while the tech-heavy Nasdaq depreciated by 1.89%.
Heading into today, shares of the world's biggest maker of health care products had lost 3.97% over the past month, outpacing the Medical sector's loss of 6.22% and lagging the S&P 500's loss of 1.7% in that time.
Investors will be eagerly watching for the performance of Johnson & Johnson in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on January 22, 2025. The company is predicted to post an EPS of $2, indicating a 12.66% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $22.54 billion, indicating a 5.37% upward movement from the same quarter last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Johnson & Johnson. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.03% higher. Currently, Johnson & Johnson is carrying a Zacks Rank of #2 (Buy).
From a valuation perspective, Johnson & Johnson is currently exchanging hands at a Forward P/E ratio of 13.62. This denotes a premium relative to the industry's average Forward P/E of 12.34.
One should further note that JNJ currently holds a PEG ratio of 2.33. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.26.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 191, this industry ranks in the bottom 24% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.